Latest Oncology News

Belantamab Mafodotin Combination Elicits Encouraging ORRs in Relapsed/Refractory Multiple Myeloma

Belantamab Mafodotin Combination Elicits Encouraging ORRs in Relapsed/Refractory Multiple Myeloma

October 1st 2022

Nichole Tucker

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

FDA Approves Futibatinib for FGFR2+ Cholangiocarcinoma

FDA Approves Futibatinib for FGFR2+ Cholangiocarcinoma

September 30th 2022

Kristi Rosa

The FDA has granted an accelerated approval to futibatinib (Lytgobi) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Targeted Therapy Generates Early Excitement in Biliary Tract Cancer

Targeted Therapy Generates Early Excitement in Biliary Tract Cancer

September 30th 2022

Ashling Wahner

As new mutational targets arise and genetic testing becomes more precise, the field of biliary tract cancer care may soon expand to accommodate a range of tailored treatments.

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial Carcinoma

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial Carcinoma

September 30th 2022

Ryan Scott

The combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelial carcinoma.

Fox Chase Cancer Center’s Jaye Gardiner Receives Award for Outstanding Postdoc From the American Society for Cell Biology

Fox Chase Cancer Center’s Jaye Gardiner Receives Award for Outstanding Postdoc From the American Society for Cell Biology

September 30th 2022

Fox Chase Cancer Center

Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, was recently awarded the Merton Bernfield Memorial Award from the American Society for Cell Biology, making her one of 18 scientists from across the country to be recognized for their achievements in the life sciences.

Latest Oncology Videos

All Oncology News

GB2064 Reduces the Level of Bone Marrow Fibrosis in Myelofibrosis

September 30th 2022

Caroline Seymour

Treatment with GB2064 monotherapy for at least 6 months led to a reduction in collagen fibrosis of the bone marrow of at least 1 grade in 4 of 5 evaluable patients with myelofibrosis, according to topline findings from a planned intermediate assessment of the phase 2a MYLOX-1 trial.

Rusfertide Leads to Promising Phlebotomy Reduction in Polycythemia Vera

September 30th 2022

Lisa Astor

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.

Patritumab Deruxtecan Looks to Make an Impact in NSCLC Treatment Paradigm with HERTHENA-Lung02

September 30th 2022

Kyle Doherty

Investigators have set their sights on confirming the viability of HER3 as a clinically actionable therapeutic target for the treatment of patients with EGFR-mutant advanced non–small cell lung cancer, with the initiation of the phase 3 HERTHENA-Lung02 trial evaluating patritumab deruxtecan.

Ivosidenib/Azacitidine Combo Elicits Survival Benefit Over Placebo in IDH1-Mutated AML

September 29th 2022

Nichole Tucker

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

E-Selectin Upregulation and Chemo Combinations Among Recent Developments in AML

September 29th 2022

Ashling Wahner

E-selectin has emerged as a viable target in acute myeloid leukemia, and agents like uproleselan have the potential the increase AML cells’ sensitivity to chemotherapies such as cladribine plus low-dose cytarabine.

Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors

September 29th 2022

OncLive Staff

Dr Shepard discusses the unpredictable course of desmoid tumors, the use of TKIs for these tumors, and findings from 2 trials presented at the 2022 ESMO Congress that may represent new treatment options for patients with desmoid tumors.

FDA Greenlights Companion Diagnostic for Selpercatinib in RET+ NSCLC and Thyroid Cancers

September 29th 2022

Kristi Rosa

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to select patients with RET fusion–positive locally advanced or metastatic non–small cell lung cancer, advanced or metastatic thyroid cancer, and advanced or metastatic medullary thyroid cancer who could be candidates to receive selpercatinib.

FDA Accepts NDA for 18F-rhPSMA-7.3 as Diagnostic Imaging Tool in Prostate Cancer

September 29th 2022

Caroline Seymour

The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.

Frontline Aumolertinib Significantly Improves PFS Over Gefitinib in EGFR-Mutated NSCLC

September 29th 2022

Ashling Wahner

Aumolertinib significantly prolonged progression-free survival vs gefitinib in treatment-naïve patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations, according to findings from the phase 3 ANEAS trial published in the Journal of Clinical Oncology.

Scott M. Welford, PhD, Named Sylvester’s Tumor Biology Research Program Co-leader

September 29th 2022

University of Miami Health System

Scott M. Welford, Ph.D., is the new Tumor Biology Research Program co-leader at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

Interventions Are Needed to Bridge Gaps Between Real-World and Clinical Trial Populations

September 29th 2022

Maurie Markman, MD

Outcomes from randomized phase 3 cancer trials are the foundation for regulatory approvals of novel antineoplastic therapeutics and, when available, treatment guidelines.

Pedmark Reduces Ototoxicity Risk in Cisplatin-Treated Pediatric Solid Tumors

September 29th 2022

Ashling Wahner

Nilay Shah, MD, discusses the importance of the FDA approval of sodium thiosulfate for pediatric patients with solid tumors, the favorable toxicity profile of the agent, and how clinical trial findings may inform future care in this population.

Dr. Schmid on the Use of Preoperative Radiation Therapy in Urothelial Carcinoma

September 28th 2022

Sebastian C. Schmid, MD

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

FDA Grants Orphan Drug Designation to SynKIR-110 for Mesothelin-Expressing Mesothelioma

September 28th 2022

Chris Ryan

The FDA has granted an orphan drug designation to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.

Giredestrant Shows Numerical PFS Benefit Vs Endocrine Monotherapy in ER+ Metastatic Breast Cancer

September 28th 2022

Kristi Rosa

Giredestrant provided a numerical, but not statistically significant, improvement in progression-free survival over physician’s choice of endocrine therapy in patients with estrogen receptor–positive, HER2-negative, locally advanced or metastatic breast cancer, according to data from the phase 2 acelERA BC study.

See All News